These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 39269573)

  • 1. Body image appearance in Parkinson's disease patients on device aided therapies.
    Proietti F; Pontani M; Pepe A; Magliozzi A; Toro S; Anzini G; Albergo G; Ricciuti R; Di Lazzaro V; Marano M
    Neurol Sci; 2024 Sep; ():. PubMed ID: 39269573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching and Combining Device-Aided Therapies in Advanced Parkinson's Disease: A Double Centre Retrospective Study.
    Georgiev D; Delalić S; Zupančič Križnar N; Socher A; Gurevich T; Trošt M
    Brain Sci; 2022 Mar; 12(3):. PubMed ID: 35326299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body mass index variations in patients with Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion: A case control study versus standard of care and subthalamic nucleus deep brain stimulation.
    Fernández-Rodríguez B; Dupouy J; Harroch E; Fabre-Delcros MH; Barthélémy C; Loubière P; Barange K; Brefel-Courbon C; Rascol O; Ory-Magne F
    Rev Neurol (Paris); 2021 Oct; 177(8):919-923. PubMed ID: 34154827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.
    Antonini A; Odin P; Pahwa R; Aldred J; Alobaidi A; Jalundhwala YJ; Kukreja P; Bergmann L; Inguva S; Bao Y; Chaudhuri KR
    Adv Ther; 2021 Jun; 38(6):2854-2890. PubMed ID: 34018146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Persistence and Monotherapy with Device-Aided Therapies: A Retrospective Analysis of an Israeli Cohort of Patients with Advanced Parkinson's Disease.
    Thaler A; Barer Y; Gross R; Cohen R; Bergmann L; Jalundhwala YJ; Giladi N; Chodick G; Shalev V; Gurevich T
    Adv Ther; 2022 May; 39(5):2009-2024. PubMed ID: 35247187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Fee-for-Service Patients with Advanced Parkinson's Disease.
    Soileau MJ; Pagan FL; Fasano A; Rodriguez-Cruz R; Yan CH; Gupta NR; Teigland CL; Pulungan Z; Schinkel JK; Kandukuri PL; Ladhani OA; Siddiqui MS
    Neurol Ther; 2023 Apr; 12(2):459-478. PubMed ID: 36652111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
    Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
    J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced Parkinson's Disease Treatment Simplification and Long-Term Outcomes with Levodopa Carbidopa Intestinal Gel: COSMOS Romanian Subanalysis.
    Simu MA; Jianu DC; Dulamea AO; Constantin VA; Popescu D; Parra JC; Szász JA
    Brain Sci; 2021 Nov; 11(12):. PubMed ID: 34942868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Liu XD; Bao Y; Liu GJ
    Front Neurol; 2019; 10():934. PubMed ID: 31507529
    [No Abstract]   [Full Text] [Related]  

  • 10. Profile Of Patients With Advanced Parkinson's disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients.
    Szász JA; Constantin VA; Orbán-Kis K; Rácz A; Bancu LA; Georgescu D; Szederjesi J; Mihály I; Fárr AM; Kelemen K; Vajda T; Szatmári S
    Neuropsychiatr Dis Treat; 2019; 15():3187-3195. PubMed ID: 32009788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?
    Catalán MJ; Antonini A; Calopa M; Băjenaru O; de Fábregues O; Mínguez-Castellanos A; Odin P; García-Moreno JM; Pedersen SW; Pirtošek Z; Kulisevsky J
    eNeurologicalSci; 2017 Sep; 8():44-53. PubMed ID: 29260038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Motor and nonmotor symptoms in patients treated with 24-hour daily levodopa-carbidopa intestinal gel infusion: Analysis of the COmedication Study assessing Mono- and cOmbination therapy with levodopa-carbidopa inteStinal gel (COSMOS).
    Kovács N; Szász J; Vela-Desojo L; Svenningsson P; Femia S; Parra JC; Sanchez-Soliño O; Bergmann L; Gurevich T; Fasano A
    Parkinsonism Relat Disord; 2022 Dec; 105():139-144. PubMed ID: 36008198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced therapies in Parkinson's disease: Long-term retrospective study.
    Merola A; Espay AJ; Romagnolo A; Bernardini A; Rizzi L; Rosso M; Espay KJ; Zibetti M; Lanotte M; Lopiano L
    Parkinsonism Relat Disord; 2016 Aug; 29():104-8. PubMed ID: 27215392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients.
    Sücüllü Karadağ Y; Saltoğlu T; Erdoğan Küçükdağli F; Öztürk Ö; Köseoğlu HT; Altiparmak E
    Turk J Med Sci; 2021 Feb; 51(1):84-89. PubMed ID: 32718129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach.
    Antonini A; Stoessl AJ; Kleinman LS; Skalicky AM; Marshall TS; Sail KR; Onuk K; Odin PLA
    Curr Med Res Opin; 2018 Dec; 34(12):2063-2073. PubMed ID: 30016901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
    Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
    Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
    Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
    Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
    Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M
    J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining Device-Aided Therapies in Parkinson's Disease: A Case Series and a Literature Review.
    Boura I; Haliasos N; Giannopoulou ΙA; Karabetsos D; Spanaki C
    Mov Disord Clin Pract; 2021 Jul; 8(5):750-757. PubMed ID: 34307748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: long-term results from COSMOS.
    Fasano A; García-Ramos R; Gurevich T; Jech R; Bergmann L; Sanchez-Soliño O; Parra JC; Simu M
    J Neurol; 2023 May; 270(5):2765-2775. PubMed ID: 36802031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.